AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...
Recursion Pharmaceuticals (NASDAQ:RXRX) announces the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at $6.50 a share, for an expected gross proceeds of ...
(RTTNews) - Shares of Recursion Pharmaceuticals, Inc. (RXRX) are trading down on Thursday morning after surging to a year-to-date high on yesterday after announcing a collaboration and $50 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback